Business Context and Reporting Period
Company: Ginkgo Bioworks Holdings, Inc. (NYSE: DNA)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Ginkgo operates two primary segments: Cell Engineering, providing biological R&D services via its Foundry and Codebase platform, and Biosecurity, offering biomonitoring and bioinformatics services (Canopy and Horizon) to government and commercial clients. The company is currently executing a restructuring plan initiated in Q2 2024 to reduce operational expenditures, including a workforce reduction of over 50% and facility consolidations.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6M 2025 | 6M 2024 |
|---|---|---|---|---|
| Total Revenue | $49,604 | $56,206 | $97,922 | $94,150 |
| Net Loss | $(60,300) | $(217,181) | $(151,257) | $(383,092) |
| Loss Per Share (Diluted) | $(1.10) | $(4.23) | $(2.77) | $(7.56) |
| Operating Cash Flow | — | — | $(91,775) | $(173,649) |
| Cash & Marketable Securities | $473,691 | — | $473,691 | — |
| Total Assets | $1,231,009 | — | $1,231,009 | — |
| Total Liabilities | $618,057 | — | $618,057 | — |
Note: Q2 2024 Operating Cash Flow is not explicitly broken out in the provided text, but 6M 2024 is $(173,649)k. Cash and Marketable Securities as of June 30, 2025, are the sum of Cash ($203,566k) and Marketable Securities ($270,125k).
Material Changes vs. Prior Period
- Revenue Mix: Cell Engineering revenue increased to $39.1M (Q2 2025) from $36.2M (Q2 2024), driven by large enterprise and government contracts. Conversely, Biosecurity revenue declined significantly to $10.5M from $20.0M due to reduced activity on a U.S. government program.
- Expense Reduction: Total operating expenses dropped dramatically to $115.1M (Q2 2025) from $279.2M (Q2 2024). This was primarily due to a $80.9M decrease in R&D expenses and a $23.0M decrease in G&A expenses, reflecting the impact of the restructuring plan and workforce reductions.
- One-Time Items: The prior year (Q2 2024) included a $47.9M goodwill impairment charge and $17.1M in restructuring charges. The current period (Q2 2025) had no goodwill impairment and only $3.7M in restructuring charges.
- Non-Cash Revenue: Q2 2025 included $1.2M of non-cash revenue, a decrease from $8.2M in Q2 2024. However, the six-month period included a $7.5M release of deferred revenue from the termination of a BiomEdit contract.
Guidance, Outlook, and Risks
- Liquidity: As of June 30, 2025, the company held $473.7M in cash and marketable securities. Management believes this is sufficient to fund operations for at least the next 12 months.
- Restructuring: The company expects workforce reductions to be substantially completed in 2025. Facility consolidation is ongoing, with potential for additional material charges related to asset impairments or lease terminations.
- Contractual Commitments:
- Google Cloud: A five-year strategic partnership with minimum annual commitments. Management estimates a potential shortfall liability of approximately $24.0M if the minimum spend is not met by August 2025.
- Twist Bioscience: An amended supply agreement requires non-refundable payments of $5.0M in April 2026 and $6.0M in April 2027.
- Risks: Key risks include the ability to raise additional capital, intense competition in synthetic biology, reliance on customers to commercialize engineered products, and the volatility of equity investments in customers (e.g., notes receivable fair value adjustments).
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $91.8M operating cash outflow over six months against the $473.7M cash balance.
- Google Cloud Liability: Confirm the status of the Google Cloud minimum spend commitment and the likelihood of incurring the estimated $24M shortfall penalty.
- Restructuring Completion: Monitor the timeline for facility subleasing and potential additional impairment charges beyond the $8.9M already recognized in the first half of 2025.
- Biosecurity Revenue: Assess the long-term viability of the Biosecurity segment given the 47% year-over-year revenue decline in Q2 2025.
- Non-Cash Revenue Quality: Review the composition of revenue to ensure future growth is driven by cash collections rather than the release of deferred revenue from terminated contracts.